MIA2

Across TCGA pan-cancer cohorts, MIA2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MIA2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where MIA2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types MIA2 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

LUAD, LSCC, and CCRCC are the cancer types where MIA2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIA2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	+0.547	<.001	9	view →
LSCC	Male	All	+0.265	<.001	7	view →
CCRCC	All	All	−0.167	<.001	7	view →
PDAC	Female	All	−0.755	<.001	6	view →
COAD	Male	All	+0.126	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MIA2–LUAD

Open the LUAD breakdown →